The Ova Antigen Delivery Reagent has been developed for efficient
in vitro
targeting of ovalbumin to antigen-presenting cells (APCs), for example, DCs. The reagent consists of a monoclonal anti-biotin antibody conjugated to ovalbumin and FITC. In combination with an appropriate biotinylated anti-receptor antibody, any desired antigen uptake receptor can be targeted.
The Antigen Delivery Module Set comprises all the reagents that are required for the isolation of DCs, antigen delivery, and subsequent analysis of antigen presentation.

Specifications for Ova Antigen Delivery Module Set

Overview

The Ova Antigen Delivery Reagent has been developed for efficient
in vitro
targeting of ovalbumin to antigen-presenting cells (APCs), for example, DCs. The reagent consists of a monoclonal anti-biotin antibody conjugated to ovalbumin and FITC. In combination with an appropriate biotinylated anti-receptor antibody, any desired antigen uptake receptor can be targeted.
The Antigen Delivery Module Set comprises all the reagents that are required for the isolation of DCs, antigen delivery, and subsequent analysis of antigen presentation.

Detailed product information

Background information

Antigen targeting to APCs via specific receptors has been used to induce effective antigen-specific T cell responses.
1–5
This allows the functional characterization of new receptors on APCs for comparison with well-characterized ones, such as CD205 (DEC205) or DCIR2 (33D1).

Downstream applications

The Ova Antigen Delivery Reagent features efficient and straightforward targeting of ovalbumin to APCs and is a powerful tool for:
  • analysis of antigen uptake, processing, and intracellular trafficking,
  • analysis of cross-presentation,
  • development of antigen delivery protocols for DC vaccination.

Resources for Ova Antigen Delivery Module Set

References for Ova Antigen Delivery Module Set

Publications

  1. Bonifaz, L. et al. (2002)
    Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8
    +
    T cell tolerance.
    J. Exp. Med. 196: 1627-1638
  2. Dudziak, D. et al. (2007) Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111
  3. Mouriès, J. et al. (2008)
    Plasmacytoid dendritic cells efficiently cross-prime naive T cells
    in vivo
    after TLR activation.
    Blood 112: 3713-3722
  4. Caminschi, I. et al. (2008) The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112: 3264-3273

Related products for
Ova Antigen Delivery Module Set

5 products available | view all

Seems like you are coming from USA!
Do you want to visit our website in your country?